Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) (NYSE: BDX) announced successful results from a 52-subject clinical trial of the BD Libertas™ Wearable Injector, designed for subcutaneous delivery of biologics. The device effectively administered 5 mL of 8 cP injections with no severe adverse reactions, showcasing high patient acceptance. All participants expressed willingness to use the device if prescribed. This marks a significant advancement in drug delivery technology, especially for larger volume biologics, as BD aims to support pharmaceutical partners in developing innovative therapies.

BD (Becton, Dickinson and Company) plans to invest approximately $1.2 billion over four years to enhance its manufacturing capacity for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across six global locations, including a new facility in Europe expected to be operational by 2023. This investment aims to improve supply continuity and accommodate increased demand from pharmaceutical companies for injectable drugs. BD has already expanded its capacity by 350 million units since 2018, reinforcing its leadership in the market.

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, reflecting a 5.1% increase from the previous quarter. This dividend will be payable on December 31, 2020 to shareholders recorded by December 10, 2020. The annual dividend rate for fiscal year 2021 is $3.32 per share. This marks the 49th consecutive year of dividend increases, underscoring BD's confidence in its long-term outlook despite challenges posed by COVID-19.

BD (Becton, Dickinson and Company) announced new reporting capabilities for COVID-19 data through the BD Synapsys™ Informatics solution (version 3.84). This enhances reporting for users of the BD Veritor™ Plus and BD MAX™ systems, both FDA authorized for SARS-CoV-2 testing. The system allows users to generate daily reports compliant with the U.S. CARES Act, streamlining mandatory reporting to health authorities. The updated capabilities aim to reduce manual reporting burdens, ultimately facilitating timely public health responses.

BD (Becton, Dickinson and Company) (NYSE: BDX) will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 8:00 a.m. ET. A live webcast will be available on the BD corporate website, with a replay accessible for seven days post-event. BD is a global leader in medical technology, dedicated to advancing health through innovative solutions. With a workforce of 65,000, the company aims to improve clinical therapy, diagnostic accuracy, and healthcare efficiency worldwide. For further details, visit www.bd.com/investors.

BD (Becton, Dickinson and Company) has acquired the Medical Business assets of CUBEX LLC, enhancing its medication management solutions. This acquisition integrates CUBEX's MedBank cloud-based software with BD's Pyxis™ Automated Dispensing Cabinets. The move aims to improve patient care across various healthcare settings, addressing challenges like medication diversion and inventory management. Approximately 40 CUBEX employees will join BD. Terms of the deal were not disclosed, but it will not affect BD's fiscal 2021 guidance.

BD (Becton, Dickinson and Company) has received authorization from Health Canada for its rapid SARS-CoV-2 antigen test, part of a government order for 7.6 million tests to enhance COVID-19 testing capabilities. The test provides results in about 15 minutes, enabling quicker decision-making at the point-of-care. Designed to ease the load on labs, this mid-nasal swab test is less invasive than traditional methods. The BD Veritor™ Plus System, already in use for other diagnostics, will support public health efforts across Canada.

BD (Becton, Dickinson and Company) (NYSE: BDX), a key player in global medical technology, announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference is scheduled for November 16, 2020, at 9:20 a.m. EDT, followed by the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 a.m. EDT. Investors can access live webcasts on the corporate website, with recordings available for at least seven days post-conference.

BD (Becton, Dickinson and Company) reported Q4 2020 revenues of $4.784 billion, a 4.4% increase year-over-year. Despite strong contributions from COVID-19 diagnostics, diluted EPS fell to $0.36, down 20%. The BD Medical segment saw a 4.9% revenue decline, while the Life Sciences segment grew 31.2% due to strong diagnostic sales. The company expects fiscal 2021 revenue growth of high single to low double-digits and adjusted EPS between $12.40 and $12.60, reflecting growth over fiscal 2020.